SM16, an Orally Active TGF- Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model
Arteriosclerosis, Thrombosis, and Vascular Biology- United States
doi 10.1161/atvbaha.107.158030
Full Text
Abstract
Available in
Date
April 1, 2008
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)